Controversial Stem-Cell Company Moves Treatment Out of the United States
By David Cyranoski,
Nature
| 01. 30. 2013
Celltex to send patients to Mexico.
US citizens who had pinned their hopes on a company being able to offer stem-cell treatments close to home will now need to travel a little farther. Celltex Therapeutics of Houston, Texas, stopped treating patients in the United States last year following a warning from regulators. A 25 January e-mail to Celltex customers indicates that the firm will now follow in the footsteps of many other companies offering unproven stem-cell therapies and send its patients abroad for treatment — but only to Mexico.
The stem-cell treatments offered by Celltex involved extracting adult stem cells from a patient, culturing them and then reinjecting them in a bid to replenish damaged tissue. It had been offering the treatment for more than a year — with one of its high-profile customers being Texas governor, Rick Perry — when the US Food and Drug Administration (FDA)
wrote to the company on 24 September 2012 advising it that the stem cells it harvested and grew were more than “minimally manipulated” during Celltex's procedures. As such, the FDA regarded the cells as drugs, which would require...
Related Articles
By Pete Shanks
| 02.27.2026
Last month, we published “The Shameful Legacy of Tuskegee” which focused on a proposed experiment in Guinea-Bissau. The study’s plan echoed the notorious Tuskegee disaster, withholding safe, effective vaccines against hepatitis B from some newborns while inoculating others. It was to be financed by the U.S. but performed by a controversial Danish team. That project provoked a multi-national outcry, leading to a remarkable response from the World Health Organization:
WHO has significant concerns regarding the study’s scientific...
By Jenn White, NPR | 02.26.2026
By Kiana Jackson and Shannon Stubblefield, New Disabled South | 02.09.2026
"MC0_8230" via Wikimedia Commons licensed under CC by 2.0
This report documents a deliberate assault on disabled people in the United States. Not an accident. Not a series of bureaucratic missteps. An assault that has been coordinated across agencies...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...